A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma

Vemurafenib, a selective inhibitor of oncogenic BRAF kinase carrying the V600 mutation, is approved for treatment of advanced BRAF mutation–positive melanoma. This study characterized mass balance, metabolism, rates/routes of elimination, and disposition of (14)C-labeled vemurafenib in patients with...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Pharmacol Res Perspect
Hlavní autoři: Goldinger, Simone M, Rinderknecht, Jeannine, Dummer, Reinhard, Kuhn, Felix Pierre, Yang, Kuo-Hsiung, Lee, Lucy, Ayala, Ruben C, Racha, Jagdish, Geng, Wanping, Moore, David, Liu, Mei, Joe, Andrew K, Bazan, Selby Patricia Gil, Grippo, Joseph F
Médium: Artigo
Jazyk:Inglês
Vydáno: BlackWell Publishing Ltd 2015
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4324687/
https://ncbi.nlm.nih.gov/pubmed/25729580
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.113
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky